Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders Assignment

Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders Assignment

Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders Assignment

The case scenario portrays HL, who has nausea, vomiting, and diarrhea. HL has a drug abuse history and likely Hepatitis C. The current drug therapy includes Synthroid, Nifedipine, Prednisone, and Flagel. On GI exam, the abdomen is non-distended but has minimal tenderness. The purpose of this paper is to discuss the likely diagnosis and recommend a drug therapy plan.

ORDER A CUSTOMIZED, PLAGIARISM-FREE PAPER HERE

Good News For Our New customers . We can write this assignment for you and pay after Delivery. Our Top -rated medical writers will comprehensively review instructions , synthesis external evidence sources(Scholarly) and customize a quality assignment for you. We will also attach a copy of plagiarism report alongside and AI report. Feel free to chat Us

Diagnosis

Hepatitis C infection is the probable diagnosis for this patient. This is a viral infection caused by the Hepatitis C virus (HCV) that causes liver inflammation and damage. Persons at risk of HCV infection include those that inject drugs, with tattoos or body piercings, and transfused infected blood (Rabaan et al., 2020). Clinical manifestations of Hepatitis C include dark yellow urine, fatigue, fever, gray- or clay-colored stools, myalgia, loss of appetite, nausea, abdominal pain, and jaundice (Manns & Maasoumy, 2022). HL has nausea, vomiting, and abdominal tenderness, which align with HCV infection. Besides, his history of drug abuse may have exposed him to contracting HCV. His history of possible HCV infection also makes Hepatitis C a likely diagnosis.

Drug Therapy Plan

Drug therapy will include Elbasvir/grazoprevir (Zepatier) 1 tablet orally once daily. Elbasvir is an antiviral medication under HCV NS5A inhibitors. It inhibits the hepatitis C virus from spreading inside the body. Grazoprevir is a protease inhibitor that decreases the amount of HCV in the body (Wang et al., 2021). This therapy aims to attain sustained eradication of HCV, which will be a success if there is a constant absence of HCV RNA in serum 12 weeks after the completion of the antiviral treatment.

Conclusion

The patient’s nausea, vomiting, mild abdominal tenderness, and possible history of HCV infection make Hepatitis C the likely primary diagnosis. Besides, he has a history of drug abuse which exposes individuals to likely HCV infection if there is sharing of needles. Medication will include Elbasvir/grazoprevir to eradicate HCV.

References

Manns, M. P., & Maasoumy, B. (2022). Breakthroughs in hepatitis C research: from discovery to cure. Nature Reviews Gastroenterology & Hepatology, 1-18. https://doi.org/10.1038/s41575-022-00608-8

Rabaan, A. A., Al-Ahmed, S. H., Bazzi, A. M., Alfouzan, W. A., Alsuliman, S. A., Aldrazi, F. A., & Haque, S. (2020). Overview of hepatitis C infection, molecular biology, and new treatment. Journal of infection and public health, 13(5), 773-783. https://doi.org/10.1016/j.jiph.2019.11.015

Wang, S. J., Huang, C. F., & Yu, M. L. (2021). Elbasvir and grazoprevir for the treatment of hepatitis C. Expert review of anti-infective therapy, 19(9), 1071–1081. https://doi.org/10.1080/14787210.2021.1874351